Theranica has announced the results of a study, recently published in the journal Pain Management, suggesting the rapid impact of Nerivio—the first and only migraine ‘neuroband’, according to the company—in reducing numbers of migraine days.
A previous study had already shown that using Nerivio every other day for eight weeks reduces the mean number of migraine days per month by four days (compared to 1.3 days in a placebo group, p<0.001). The prospective, randomised, double-blind clinical trial evaluated the efficacy of remote electrical neuromodulation (REN) treatment applied every other day for the prevention of migraine. It included a four-week baseline (observation) phase and an eight-week double-blind intervention phase. The number of monthly migraine days per group was calculated in two-week intervals and compared between the groups.
The present study, announced recently by Theranica, was a post-hoc analysis of that prospective study—but involved evaluating the preventive response at timepoints earlier than eight weeks. The findings were that, already—after two weeks of usage—there was a statistically significant mean reduction of 1.7 migraine days per month, compared to 0.8 days in the placebo group (p=0.036). In addition, after four weeks of usage, a 3.1-day reduction (compared to 1.5 days in placebo, p=0.025) was observed.
In a press release, Theranica claims that this new publication suggests rapid, sustained reductions in monthly migraine days can be achieved when using Nerivio every other day.
“These results suggest that the preventive impact of REN kicks in rather early after starting it every other day,” said Andrea Harriott (Massachusetts General Hospital/Harvard Medical School, Boston, USA), who is one of the authors of the new study. “This study demonstrates that Nerivio addresses patients’ preferences by providing rapid onset of action, coupled with high efficacy and low occurrence of side-effects.”
In another study, published earlier this year in the journal Headache, people living with migraine were asked to rate which factors mattered most to them in order to be satisfied with their preventive treatment. Effectiveness and speed of onset were the top-ranking factors, and other studies have also found similar results, showing that people with migraine value treatments that start working fast, Theranica further claims.
“For medical solutions to have real patient-centred meaning, you must be hyper-attentive and committed to understanding patient needs, and be open to creating out-of-the-box therapies to migraine management,” said Alon Ironi, CEO and co-founder of Theranica. “Migraine disease is extremely debilitating. People living with migraine need fast results so that they can continue with their normal activities, which is why we are so excited about these latest prevention data. It further demonstrates the important clinical benefits that Nerivio offers to adults and adolescents living with this neurological disorder.”